|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,095 USD | +0.02% |
|
+2.44% | +24.93% |
| 12/07 | UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating | MT |
| 11/07 | Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183 | MT |
Jan 8 (Reuters) - Regeneron Pharmaceuticals said on Monday its franchise of eye drug Eylea recorded preliminary sales of $1.34 billion in the United States in the fourth quarter.
Wells Fargo analyst Mohit Bansal last week pegged consensus Wall Street estimates for U.S. sales of Eylea at $1.53 billion.
The newer higher dose version of the drug generated about $123 million in sales in the quarter in the United States. (Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 1,095 USD | +0.02% | +2.44% | 118B | ||
| 60.42 USD | +0.29% | +1.60% | 205B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +24.93% | 118B | |
| +19.61% | 126B | |
| +24.45% | 27.87B | |
| -16.74% | 20.95B | |
| -14.80% | 16.92B | |
| -13.51% | 16.18B | |
| +11.00% | 14.84B | |
| -47.10% | 14.79B | |
| +53.48% | 14.08B | |
| +144.69% | 12.57B |
REGENERON PHARMACEUTICALS, INC. 
